News

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
Novavax has been available since 2022 through a pandemic-era Emergency Use Authorization. A decision on full approval – which ...
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...
The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...
Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...
Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...
WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax's COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...
The FDA was on track to grant Novavax full approval by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss ...